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SUMMARY
There is a need for a more efficient vaccine against the bacterium Y. pestis, the agent of
pneumonic plague. The F1-LcrV subunit vaccine in alhydrogel is known to induce humoral
immunity. In this study, we utilized dendritic cells to investigate cellular immunity. We
genetically engineered the LcrV virulence protein into the αDEC-205/CD205 monoclonal
antibody and thereby targeted the conjugated protein directly to mouse DEC-205+ DCs in situ. We
observed antigen-specific CD4+ T cell immunity measured by intracellular staining for interferon-
γ in three different mouse strains (C57BL/6, BALB/c, and C3H/HeJ), while we could not observe
such T cell responses with F1-V vaccine in alhydrogel. Using a peptide library for LcrV protein,
we identified two or more distinct CD4+ T cell mimetopes in each MHC haplotype, consistent
with the induction of broad immunity. When compared to nontargeted standard protein vaccine,
DC targeting greatly increased the efficiency for inducing IFN-γ producing T cells. The targeted
LcrV protein induced antibody responses to a similar extent as the F1-V subunit vaccine, but Th1-
dependent IgG2a and IgG2c isotypes were observed only after αDEC-205:LcrV mAb
immunization. This study sets the stage for the analysis of functional roles of IFN-γ producing T
cells in Y. pestis infection.
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INTRODUCTION
Yersinia pestis (Y. pestis), the causative agent of plague or Black Death, is again drawing
attention due to its potential use as a biological weapon [1,2]. Bubonic plague is the most
common clinical form of disease and is characterized by swollen lymph nodes (buboes)
*Correspondence should be addressed to Ralph M. Steinman, Laboratory of Cellular Physiology and Immunology, The Rockefeller
University, New York, NY 10065-6399. Phone: 212-327-8106; Fax: 212-327-8875; steinma@mail.rockefeller.edu.
CONFLICT OF INTEREST STATEMENT
R. M. Steinman is a consultant to Celldex, which is developing human DEC-205-based vaccines. Other authors have no conflict of
interest.
NIH Public Access
Author Manuscript
Eur J Immunol. Author manuscript; available in PMC 2010 May 5.
Published in final edited form as:
Eur J Immunol. 2008 January ; 38(1): 20–29. doi:10.1002/eji.200737799.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
following bites by infected fleas. If untreated, it can progress to the life-threatening
septicemic and pneumonic forms of plague. The latter form also occurs via contaminated
respiratory droplets, or even by artificially generated aerosols containing Y. pestis and is
particularly dangerous because of its high contagiousness and mortality [1]. There is a need
to develop more effective vaccines for pneumonic plague.
The existing vaccines against Y. pestis that have been used in man are either attenuated or
killed organisms, and are insufficiently effective against pneumonic diseases [3]. In a
murine model, a subunit vaccine composed of recombinant F1 and LcrV protein (F1-V) has
been demonstrated to induce protective responses [4]. F1 antigen is an extracellular capsular
antigen, encoded on a 110 kb plasmid (pMT-1) and exerting anti-phagocytic activity [5].
Protective immunity via F1 has been shown in a murine model, and in humans, F1 elicits
strong antibody responses following immunization with purified native antigen [6,7]. The
other component of the current subunit vaccine, LcrV, is a secreted multifunctional protein
encoded on a 70 kb plasmid (pCD1). LcrV regulates the delivery of other effector molecules
of Y. pestis or Yops into host cells upon contact via a type III secretion system (TTSS) [8,9].
LcrV also is reported to have immunosuppressive potential by stimulating IL-10 secretion
[10]. Although LcrV alone has been shown to protect mice against infection with either F1-
positive or F1-negative strains, the F1-V combination provides better protection than either
subunit vaccine alone, and moreover, it protects mice against pneumonic plague [11–13].
Recent studies have indicated that besides humoral immunity, the induction of cellular
immunity might be an important goal for a plague vaccine. CD4+ T cells are able to produce
high levels of Th1 cytokines such as IFN-γ, which can activate macrophages to kill
intracellular pathogens, and helper T cells also contribute to antibody-based immunity. In
addition, CD4+ T cells can exert cytolytic activity on MHC class II-bearing targets [14]. It
was first noted that treatment of mice with exogenous IFN-γ plus TNF-α inhibited the
multiplication of Y. pestis in vivo, thereby providing protection against intravenous
challenge against 10 MLD of LcrV+ Y. pestis KIM [15]. Likewise, LcrV antigen co-
encapsulated with IFN-γ induced higher antigen-specific systemic immune responses [16].
Moreover, Stat-4 deficient mice, which have low levels of IFN-γ production, were poorly
protected from Y. pestis GB by the s.c. route, despite producing as high levels of serum
antibody as wild type controls [17]. A protective role of CD4+ T cells in Y. enterocolitica
infection was recently demonstrated by Smiley and colleagues, where three LcrV-specific
CD4 epitopes were identified that are presented in the context of the murine I-Ab class II
MHC molecule [18]. This group further showed that the transfer of Y. pestis-primed T cells
to naive B cell deficient mice (μMT) protected against attenuated Y. pestis (KIM D27)
intranasal challenge [19]. In another study, Parent et al concluded that IFN-γ, TNF-α and
NOS2 (nitric oxide synthase 2) are key elements of cellular immunity during pulmonary Y.
pestis (KIM D27) infection [20]. Therefore, an effective plague vaccine may need to prime
not only humoral immunity but also strong Th1 type cellular immunity.
In this study, we targeted the LcrV virulence protein to dendritic cells (DCs), which are
potent and specialized antigen-presenting cells, with the aim of generating more effective T
helper cells. DCs are known as “nature’s adjuvants”, and various potential strategies to
exploit DCs in vaccine design have been suggested [21]. Recent studies provide a new
avenue to DC-based vaccines by using an anti-mouse DC monoclonal antibody (mAb),
specifically αDEC-205/CD205 mAb, to target vaccine antigens directly to DCs in situ [22–
24]. Antigens incorporated within αDEC-205 mAb are efficiently and selectively targeted to
DCs, leading to greatly enhanced presentation to T cells when compared to nontargeted
antigen. This targeting strategy improves T cell vaccination, e.g. intensified and protective
CD4 T cell immunity is induced to HIV gag p24 and p41 proteins by DEC-205-targeting
and this provided protection against an airway challenge with recombinant vaccinia-gag
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virus [23]. Using anti-DEC/LcrV fusion mAb together with DC maturation stimuli, we
observed strong and broad antigen-specific Th1 type CD4+ T cell immunity as well as
humoral immunity including high titers of Th1 type antibodies, which was not observed
with the recombinant subunit F1-V vaccine. This study provides a new way to study the
functional roles of Th1 type T cells in plague and suggests a way to the development of
vaccines that include strong cell mediated as well as humoral immunity.
RESULTS
Generation of fusion mAb of LcrV protein engineered into anti-DEC-205
To target LcrV protein to DCs directly in vivo, the full length LcrV sequence was first
codon optimized to improve expression and cloned in frame into the heavy chain of anti-
mouse DEC-205 mAb as described [25]. Due to the insertion of LcrV, which has a mass of
37 kDa, the heavy chain of the chimeric mAb was detected at ~ 97 kDa, following SDS-
PAGE and either Coomassie staining or western blotting (Fig. 1A and C). To verify that the
chimeric mAb bound properly to mouse DEC-205 receptor, a stable Chinese Hamster Ovary
(CHO) cell transfectant, expressing mouse DEC-205 receptor on the surface, was stained
with various concentrations of the conjugated- or non-conjugated mAbs. By FACS, the
αDEC-205:LcrV mAb bound to DEC-205 receptor as well as the non-conjugated or “empty
DEC” mAb (Fig. 1D). In addition, soluble LcrV protein was generated from the stable CHO
cell transfectant and purified using an anti-FLAG affinity column (Fig. 1B). To visualize the
specificity of targeting in situ, lymph nodes (LNs) sections were prepared after
administration of Alexa488-conjugated αDEC-205:LcrV, or isotype control (mouse IgG1)
mAb. Staining for the injected mAb was confined to dendritic profiles in T cell area (Fig.
1E, green signal). These profiles were double labeled for anti-DEC-205 applied to the
section (Fig. 1E, blue signal). Taken together, these data indicate the successful generation
of the chimeric mAb and specific in vivo targeting to DEC-205+ DCs.
DEC-205 targeting of LcrV enhances antigen presentation to T cells and broad CD4 T cell
immunity in vivo
To determine whether the chimeric mAb could induce T cell immune responses, groups of
C57BL/6 (H-2b), BALB/c (H-2d), and C3H/HeJ (H-2k) mice were injected with a single
dose of αDEC-205:LcrV mAb s.c. in the presence of DC maturation stimuli, which was the
combination of 50 μg of poly IC and 25 μg of agonisticαCD40 mAb. Fourteen to 21 days
later, splenocytes were harvested and restimulated with LcrV peptide pools, and the
frequency of IFN-γ secreting antigen-specific CD4+/CD8+ T cells were examined by
ELISPOT (data not shown) and intracellular cytokine staining (Fig. 2). The peptide library
that we used was divided into 8 pools of 11 overlapping 15-mer peptides staggered every 4
amino acids along the entire LcrV sequence (see methods). For C57BL/6 mice, CD4+ T cell
responses were noted to peptides in pool 2 and 3. For BALB/c, peptide pools 3, 5, and 6
were recognized by CD4+ T cells, and for C3H, peptide pools 3 and 6 contained the most
reactive epitopes. CD8+ T cell responses were not observed. The reactive peptide pools were
then broken down into individual peptides. The reactive mimetope peptides are summarized
in Table 1. At least two (C57BL/6, and C3H) and three different mimetopes (BALB/c) were
identified. We repeated this experiment twice and summarized the frequency of IFN-γ
secreting CD4+ T cells in Table 2. These data indicated that the targeting of LcrV protein to
DCs induced a broad immune response by CD4+ T cells in several MHC haplotypes.
DEC-205 targeting increases the efficiency of inducing LcrV-specific CD4 T cell responses
To determine the efficiency of targeting strategy, increasing doses of αDEC-205:LcrV mAb
in the presence of poly IC and αCD40 were administered into C57BL/6 (data not shown) or
BALB/c mice and 14 days later, the frequency of IFN-γ and/or IL-2 secreting LcrV-specific
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CD4+ T cells was measured. In comparison, soluble nontargeted LcrV protein with poly IC
and αCD40 as well as F1-V recombinant protein with alhydrogel as an adjuvant were also
included (Fig. 3A). The data showed an increased frequency of IFN-γ and/or IL-2 secreting
CD4+ T cells with αDEC-205:LcrV mAb immunization in mice, while non-targeted soluble
LcrV protein required at least 100 μg to induce antigen-specific T cell responses. Moreover,
similar T cell responses were not observed in mice immunized with F1-V adsorbed in alum
adjuvant. This data demonstrated that the targeting strategy increases the efficiency of
eliciting IFN-γ producing T cell responses.
We also tested different peptide doses during the immune assay and determined that most T
cells responded to antigen at 0.2 μM peptide or higher (Fig. 3B). Based on the data, we
decided to use 10 μg of αDEC-205:LcrV mAb, 100 μg of soluble protein, or 10 μg of F1-V
recombinant protein for immunization, and 2 μM of reactive peptide for restimulation in this
study unless otherwise indicated.
Anti-DEC-205:LcrV immunization enhances CD4+ T cell immunity relative to other
immunization approaches
We compared the response to DC-targeted LcrV with other methods of immunization. When
we injected soluble LcrV protein, either 10 μg or 100 μg per mouse, with standard
adjuvants, complete Freund’s adjuvant (CFA), the immune responses were weak compared
with 10 μg of DC-targeted αDEC-205:LcrV mAb in the presence of poly IC and αCD40 as
adjuvants (Fig. 4A). Again, F1-V recombinant protein adsorbed in alum adjuvant did not
induce IFN-γ secreting CD4+ T cells. In addition, DEC-205 was essential for the enhanced
CD4 T cell immunity induced by DC-targeted LcrV protein, because such responses were
not observed in DEC-205−/− mice (Fig. 4B). Thus, the data suggested that the targeting of a
vaccine protein to DCs improves CD4+ T cell immunization relative to other approaches
including standard soluble protein immunization as well as F1-V subunit vaccine.
Strong antibody responses to αDEC-205:LcrV mAb administration
To study humoral immunity induced by DC-targeted LcrV protein, we tested antibody
responses with graded doses of αDEC-205:LcrV mAb, soluble LcrV protein, or F1-V.
Antibody titres increased with increasing doses of protein (Fig. 5A). Also the titers induced
by 10 μg of F1-V with alhydrogel were comparable to those induced by either 10 μg of
αDEC-205:LcrV or 100 μg of soluble LcrV protein in the presence of poly IC and αCD40 as
adjuvants (Fig. 5A).
Next, anti-LcrV antibody titers for individual IgG isotypes were examined (Fig. 5B). Again,
a single immunization of αDEC-205:LcrV mAb with adjuvants induced serum levels of each
isotype that were comparable to F1-V immunization. The IgG1 and 2b isotypes were
predominant as described in previous studies [4]. However, the IgG2a (BALB/c) or IgG2c
(C57BL/6, data not shown) isotype was observed primarily in mice immunized with
αDEC-205:LcrV mAb, with little or no IgG2c/2a in the F1-V immunized group (Fig. 5B).
The IgG2c/2a isotypes reflect the influence of Th1 type helper T cells and are consistent
with the observation that anti-DEC-205 targeted protein vaccine is a superior way to induce
this type of cell-mediated immunity.
DISCUSSION
It is possible that a successful vaccine for plague needs to induce combined cellular and
humoral immune responses against virulence determinants with minimal side effects. The
need for cellular immunity was first indicated by the studies of Nakajima and Brubaker who
noted protective effects of exogenous IFN-γ and TNF-α [15]. Elvin et al then reported that
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Stat-4 deficient mice, which are only able to produce very low amounts of IFN-γ, were
poorly protected by s.c. infection with Y. pestis even though they produce high levels of
antibody similar to controls [17]. A protective role of CD4+ T cells in Y. enterocolitica
infection was directly demonstrated by Smiley and colleagues, where three LcrV-specific
CD4 epitopes were identified that are presented in the context of the murine I-Ab class II
MHC molecule [18]. This group further showed that the transfer of Y. pestis-primed T cells
to naive B cell deficient mice (μMT) protected against attenuated Y. pestis (KIM D27)
intranasal challenge [19]. Here we have addressed approaches to induce strong T cell
immunity of the IFN-γ producing Th1 type in otherwise naive mice.
The existing plague vaccines, such as killed whole-cell vaccine and attenuated vaccine,
induce protection against bubonic plague, but the vaccines evoke severe side effects and do
not provide protection against pneumonic plague [3]. A subunit vaccine composed of F1 and
V proteins has provided the most promising efficiency based on the data obtained from
small animal models [4]. Along with evidence showing protection through adoptive
serotherapy, the general mechanism by which F1-V subunit vaccine provided protection is
considered to be antibody-mediated, and especially, the IgG1 isotype antibody plays an
important role [26,27].
It has been known that Y. pestis targets immune cells during infection, and through its
specialized delivery system or TTSS, it has a range of anti-host functions from anti-
phagocytic activity to immunosuppression [28]. Therefore, to induce protective immunity, it
may be valuable to activate immune cells such as DCs and macrophages that are targeted by
Y. pestis. Th1 cytokines might provide a way to bring about this activation and/or overcome
the immunosuppression that is induced by Y. pestis. In addition, Th1 type immune responses
can provide “help” for antibody-based immunity as well as the generation of memory
responses [14,29]. For these purposes, we have utilized DCs and a DC-targeting strategy to
induce immunity. We took a monoclonal antibody against a specific DC receptor, anti-
DEC-205/CD205 mAb and genetically engineered the LcrV antigen of Y. pestis into the
antibody heavy chain. Our data show the improved quality and quantity of T cell responses
induced by DEC-205 targeted antigen.
Recently, LcrV protein epitopes recognized by CD4 T cells were identified in H-2b and
H-2d mice in two independent studies [18,30]. Since these studies depended on standard
protein immunization for priming, high concentrations of protein or peptides, or sometimes,
prime boost strategies were required to induce detectable CD4 T cell responses. In addition,
to detect immune responses, it was necessary to use either a proliferation assay with bone-
marrow derived macrophages and T cell hybridomas or ELISA for IL-2 released during in
vitro restimulation with splenic antigen presenting cells (APCs). Generating T cell
hybridomas is time-consuming and also IL-2 is not the best reflection of Th1 cytokines. In
contrast, we assayed the immunity that was induced by in situ targeting of antigen to DCs
with intracellular cytokine staining of immune spleen cells challenged for 6 hrs with a
peptide library of 15-mers spanning the full length of LcrV protein. In this way we could
document the presence of sizeable T cell responses with minimal tissue culture
requirements. Our data showed that a single dose of smaller amounts of antigen conjugated
to αDEC-205:LcrV mAb induced stronger IFN-γ secreting CD4+ T cell responses when
compared to nontargeted soluble protein (Fig. 3A). In addition, relatively low doses (0.2
μM) of the mimetope peptides were used to activate the primed T cells in the assays (Fig.
3B). We also could observe broad T cell immunity induced by a single dose of DC-
targeting, since we identified distinct CD4 T cell mimetopes in three different MHC
haplotypes that were tested and at least two peptides in each haplotype (Fig. 2 and Table 1
and 2). We noted that the DC targeting strategy enhanced CD4+ T cell responses relative to
nontargeted soluble protein with standard adjuvants such as CFA or alhydrogel (Fig. 4A).
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Interestingly the peptides that were recognized following DEC-205 based immunization
were identical to those reported by Parent et al and Shim et al.
During primary immune responses, CD4+ T cells control affinity maturation and isotype
switching by antigenic-specific B cells [31]. Cytokines secreted from the helper T cells are
important to determine isotype switching, such as IFN-γ (Th1) for IgG2a (BALB/c) or
2c(C57BL/6) production, or IL-4 (Th2) for IgG1, respectively [32]. As described in a
previous study, DC targeting leads to a broad range of different antibody isotypes, or a
combination of Th1 and Th2 responses [24]. In this study, we also observed that LcrV
antigen targeted to DCs induced multiple isotypes including IgG1, 2a/2c, or 2b in serum
(Fig. 5). However, F1-V recombinant protein vaccine could not induce Th1 isotype antibody
as much as αDEC-205:LcrV mAb immunization, even though it generally leads to high
titers of IgG1 and 2b isotypes.
Here we have used a combination of TLR3 ligand poly IC and agonistic αCD40 mAb as DC
maturation stimuli to overcome T cell tolerance [25,33–35]. Further study of active
adjuvants is required. We observed that poly IC by itself did not lead to a primary immune
response that was strong enough to be detected in our assays. We are now investigating the
potential of poly IC alone as an optimal DC adjuvant in conjunction with a prime boost
strategy, and we are also interested in whether the CD4+ T cell responses observed in the
current study translate into a better quality and quantity of humoral immunity, especially
memory. The contribution of the cellular immunity observed with our DC-targeting strategy
should also be investigated in protection studies, especially against an aerosol challenge of
Y. pestis.
MATERIALS & METHODS
Mice
C57BL/6 (H-2b), BALB/c (H-2d), and C3H/HeJ (H-2k) mice were purchased from Taconic,
and DEC-205−/− mice (B6 background) are available from Jackson labs. All mice were
maintained under specific pathogen-free conditions and used at 5–7 wks of age according to
the guidelines of our Institutional Animal Care and Use Committee.
Construction and production of fusion mAbs and protein
The mammalian codon-optimized cDNA encoding LcrV (GenBank accession No.
DQ917566) open reading frame of full length was generated by PCR, and was cloned in
frame with the carboxyl terminus of the heavy chain of mouse anti-DEC-205 mAb described
in our previous study [25]. αDEC-205:empty mAb is a mouse anti-DEC-205 mAb without
any antigen insertion to the carboxyl terminus. The fusion αDEC-205:LcrV mAb and a
control Ig:LcrV fusion mAb were produced by transient transfection into 293T cells using a
calcium-phosphate method as described, and purified on Protein G column (Amersham
Pharmacia Biotech) [25]. Soluble LcrV protein was generated by adding a signal peptide
and FLAG epitope tag to the NH2-terminus, expressed by stable transfection to Chinese
Hamster Ovary (CHO) cells, and purified on anti-FLAG M1 affinity column (Sigma)
according to manufacturer’s protocol. A recombinant F1-V protein from U.S. Army Medical
Research Institute of Infectious Diseases (USAMRIID, Frederick, MD) has been described
[36].
Immunization
Mice were injected intraperitoneally (i.p.) or subcutaneously (s.c.) in the hind footpads with
fusion mAb, unconjugated αDEC-205 mAb, control Ig, or soluble LcrV protein in the
presence or absence of adjuvants, which were 50 μg of poly IC with 25 μg of 1C10 agonistic
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anti-CD40 mAb (αCD40) per mouse. Soluble LcrV protein was also administered s.c. with
complete Freund’s adjuvant (CFA). F1-V recombinant protein was administered with
alhydrogel (2.0% Alhydrogel, Superfos Biosector, Vedbaek, Denmark).
LcrV peptides
15-mer peptides spanning the entire LcrV sequence and overlapping by 11 amino acids (aa)
were synthesized by the Proteomics Resource Center (The Rockefeller University). The
library was divided into 8 pools of 11 peptides except peptide pool number 8, which was
composed of 10 peptides. The peptide pools spanned from aa 1–46 (pool 1), aa 36–86 (pool
2), aa 76–128 (pool 3), aa 118–170 (pool 4), aa 160–210 (pool 5), aa 200–250 (pool 6), aa
240–291 (pool 7), and aa 281–326 (pool 8) of the LcrV protein.
Intracellular cytokine staining and surface staining
To detect LcrV-specific T cell immunity, spleen or lymph nodes cells were stimulated with
pools of peptides (2 μM or indicated concentrations) or medium alone in the presence of a
co-stimulatory anti-CD28 mAb (clone 37.51) for 6 hrs. Brefeldin A was added for the last 4
hrs to accumulate intracellular cytokines. Cells were then washed, incubated with anti-
mouse-CD3, CD4 or CD8 mAbs for 20 min at 4°C after blocking Fcγ receptor with αCD16/
CD23 antibody. Following fixation with Cytofix/Cytoperm Plus ™ (BD PharMingen), cells
were stained for intracellular IFN-γ or IL-2 for 15 min at room temperature. All mAbs were
purchased from BD PharMingen. Data were collected using FACS Calibur and analyzed by
FlowJo (Tree Star).
ELISA for anti-LcrV antibodies
To detect LcrV specific antibody, high binding ELISA plates (BD Falcon) were coated with
10 μg/ml of LcrV protein overnight at 4°C. Plates were washed 3 times with PBST (PBS
and Tween 20, 0.1%) and blocked with PBST-BSA 5% for 1 hr at 37°C. Serial dilutions of
serum were added to the plates and incubated for another 1 hr at 37°C. Various secondary
goat anti-mouse Fc specific antibodies conjugated with horseradish peroxidase (Southern
Biotech) were then added and visualized with OPD (o-phenylenediamine, Sigma) tablet at
room temperature for 15–30 min. The reported titers represent the highest dilution of sample
showing an OD450 higher than 0.1, and the data was presented as the log antibody titer.
Some of the data were shown as OD450 values.
Microscopy
Alexa488-conjugated αDEC-205:LcrV, or isotype control (mouse IgG1) antibodies were
prepared using the Alexa Fluor® 488 protein labeling kit (Molecular Probes). A
deconvolution microscope (Olympus America, Melville, NY), and one-, two- or three-color
fluorescence labeling was used with antibodies and fluorochromes listed in the micrographs.
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Figure 1.
Characterization of a fusion anti-DEC-205 mAb and LcrV protein and its in situ targeting to
DEC-205+ cells in the T cell areas of lymph node. M, molecular weight standards (kDa).
Coomassie Blue staining of (A) fusion mAb and (B) LcrV protein. (C) Western blotting of
unconjugated mouse IgG1 (αDEC-205:empty), andαDEC-205:LcrV mAb. (D) FACS
staining data showing binding capacity of unconjugated αDEC-205 (lower) and
αDEC-205:LcrV mAb (upper) to DEC-205 receptor by using stable transfectant CHO cells
(CHO/mDEC-205). (E) Microscopy to show in situ targeting of αDEC-205:LcrV mAb to
the inguinal lymph nodes, using Alexa488-conjugated αDEC-205:LcrV mAb (green, left) or
isotype control Ab (right) injected into the hind footpads (40 μg/footpad) 6 hrs earlier.
Sections were also stained with PE-conjugated B220 to mark the B cell areas (red) and
OLLAS epitope tagged anti-DEC-205 antibody (manuscript submitted) to localize
endogenous DEC-205+ cells (blue).
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Figure 2.
CD4+ T cell responses to a single dose of αDEC-205:LcrV mAb. C57BL/6 (A), BALB/c
(B), and C3H/HeJ (C) mice were immunized s.c. with αDEC-205:LcrV mAb (10 μg) in the
presence of poly IC (50 μg) and agonistic αCD40 mAb (25 μg) and 2–3 wks later, splenic
cells were restimulated with peptide pool 1–8. Percentages of IFN-γ secreting CD3+/CD4+ T
cells were assessed by intracellular cytokine staining (thick-lined boxes). These experiments
were repeated three times in each strain with similar results (see Table 2).
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Figure 3.
Strong CD4+ T cell responses to a single dose of αDEC-205:LcrV mAb. (A) BALB/c mice
were injected s.c. with graded doses of αDEC-205:LcrV mAb, F1-V, or LcrV protein in the
presence of adjuvants (poly IC and αCD40 for αDEC-205:LcrV mAb and LcrV protein, and
alhydrogel for F1-V protein). Two weeks later, splenic T cells were restimulated with LcrV
reactive peptides from pool 5 (BALB/c, LKIYSVIQAEINKHL, aa164–178) and IFN-γ+ or
IL-2+ secreting CD4+ T cells were assessed by intracellular cytokine staining. Background
activity (<0.01%) of PBS or maturation stimulus alone (25 μg αCD40 mAb and 50 μg of
poly IC) injected mice was subtracted from the percentage of IFN-γ+ or IL-2+ CD4+ cells.
One of two similar experiments with two mice pooled in each experiment. (B) BALB/c mice
were immunized with 10 μg of αDEC-205:LcrV mAb with maturation stimuli, and 2 weeks
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later, splenocytes were restimulated with graded doses of LcrV reactive peptides described
in (A). The percentage of IFN-γ+ CD4+ cells was assessed by intracellular cytokine staining.
One representative experiment of two.
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Figure 4.
Comparison of CD4+ T cell responses between nontargeted protein immunization and DC-
targeted protein. (A) BALB/c mice were injected s.c. with αDEC-205:LcrV mAb (10 μg),
F1-V (10 μg), control Ig (10 μg), or LcrV protein (10 μg or 100 μg) in the presence of
adjuvants (poly IC and αCD40 for αDEC-205:LcrV mAb, control Ig, alhydrogel for F1-V
protein, and CFA for LcrV protein). Two weeks later, splenic T cells were restimulated with
LcrV reactive peptides from pool 5 (BALB/c, LKIYSVIQAEINKHL, aa164–178) and IFN-
γ+ secreting CD4+ T cells were assessed by intracellular cytokine staining. One of two
similar experiments with two mice pooled in each experiment. (B) C57BL/6 or DEC-205−/−
mice were immunized with 10 μg of αDEC-205:LcrV mAb with maturation stimuli, and 2
weeks later, splenocytes were restimulated with LcrV reactive peptides (KILAYFLPEDA
aa73–83). The percentage of IFN-γ+ CD4+ cells was assessed by intracellular cytokine
staining. One representative experiment of two.
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Figure 5.
Antibody response following αDEC-205:LcrV mAb immunization. (A) Anti-LcrV IgG
antibody titers after 2 weeks of i.p. injection with graded doses of F1-V adsorbed in alum,
αDEC-205:LcrV mAb, and LcrV protein in the presence of adjuvants (50 μg of poly IC and
25 μg of αCD40), or adjuvants alone. At least, two similar experiments were repeated and
one representative data was shown. (B) Anti-LcrV antibody titers for individual IgG
isotypes after 2 weeks of i.p. injection with PBS, F1-V (10 μg) adsorbed in alum,
αDEC-205:LcrV (10 μg) mAb in the presence of adjuvants (50 μg of poly IC and 25 μg of
αCD40), or adjuvants alone. Symbols represent individual mice, and the horizontal line
represents the mean value of each group. One representative experiment of three.
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Table 1
LcrV mimetope peptides recognized by mice immunized with αDEC-205:LcrV mAb
Different strains of mice were immunized s.c. with αDEC-205:LcrV mAb (10 μg) in the presence of poly IC
(50 μg) and agonistic αCD40 mAb (25 μg) and 2–3 wks later, splenic cells were restimulated with peptide
pool 1–8. Then the pools were broken down into individual peptides to identify peptide mimetopes recognized
by the immune CD4+ T cells.
Strain and MHC haplotype LcrV peptide pool Reactive peptide
C57BL/6 H-2b 2 KILAYFLPEDA (aa 73–83)
3 EFLEFLESSPNTQW (aa 103–113)
BALB/c H-2d 3 TQWELRAFMAV (aa 111–121)
5 LKIYSVIQAEINKHL (aa 164–178)
6 KILEKMPQTTIQV (aa 214–226)
C3H H-2k 3 SSPNTQWELRA (aa 107–117)
6 EEIFKASAEYK (aa 204–214)
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Table 2
CD4+ T cell responses to LcrV in three different mice strains after a single immunization
with αDEC-205: LcrV mAb
Different strains of mice were immunized s.c. with αDEC-205:LcrV mAb (10 μg) in the presence of poly IC
(50 μg) and agonistic αCD40 mAb (25 μg) and 2–3 wks later, splenic cells were restimulated with peptide
pool 1–8 and reactive peptides identified as in Table 1. The data shown are mean values for IFN-γ secreting
CD4+ T cells in 3 experiments without or with restimulation with the dominant recognized peptide.
Stain and MHC haplotype
% IFN-γ+ cells in CD4+ T cells
+ peptide − peptide
C57BL/6 H-2b 0.19 ± 0.035 0.014 ± 0.005
BALB/c H-2d 0.36 ± 0.045 0.023 ± 0.006
C3H H-2k 1.29 ± 0.34 0.03 ± 0.01
*
C57BL/6, KILAYFLPEDA; BALB/c, LKIYSVIQAEINKHL; C3H/HeJ, EEIFKASAEYK
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